# TWB-103 for Treating Lower Limb Ulcers on Patients With DM

> **NCT03624023** · PHASE1,PHASE2 · COMPLETED · sponsor: **Transwell Biotech Co., Ltd.** · enrollment: 10 (actual)

## Conditions studied

- Diabetic Foot Ulcer

## Interventions

- **DRUG:** TWB-103

## Key facts

- **NCT ID:** NCT03624023
- **Lead sponsor:** Transwell Biotech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-12-19
- **Primary completion:** 2021-07-09
- **Final completion:** 2021-07-09
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2023-07-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03624023

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03624023, "TWB-103 for Treating Lower Limb Ulcers on Patients With DM". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03624023. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*